The study evaluated serum biomarkers of lipid peroxidation, systemic inflammation, and axonal integrity in 100 randomly selected patients with ALS and included 100 healthy controls to allow for a meaningful...
Howard Berman, Ph.D., the Company’s Founder and current Executive Chairman and Director, has stepped down from his roles, following the CEO transition process initiated in November 2024. ...
Study results demonstrate significant reduction in regulatory T cell (Treg) function and significant increase in circulating pro-inflammatory cytokines and chemokines in patients with FTD ...
Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance T-cell (Treg) function in patients with...
─ Virtual Webinar on Tuesday, Feb. 17 at 3 p.m. ET / 12 p.m. PT ─ Will feature discussion and insights from Fred Grossman, D.O., FAPA; Stanley Appel, M.D.;...
- Dr. Reddy’s Laboratories, Inc., a subsidiary of Coya’s current strategic collaborator, makes a $10 million investment - Greenlight Capital, Coya’s...
Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance Treg function, releases the following letter...
Robust target engagement was observed, with statistically significant increases in regulatory T-cell (Treg) suppressive function and Treg numbers beginning as early as two weeks post-dosing and sustained...
The CTA No Objection Letter from Health Canada allows for initiation of patient enrollment in the ALSTARS Trial at Canadian ALS centers. The ALSTARS Trial is a phase 2, placebo-controlled study...
The ALSTARS Trial is a Phase 2, multi-center, randomized, double-blind, placebo-controlled study to assess the safety and efficacy of COYA 302 in patients with amyotrophic lateral sclerosis (ALS) being...